Tuesday 13 October 2026
Export CAPR’s income statement to Excel — free account
Capricor Therapeutics, Inc.
CAPR Healthcare Biotechnology
Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.
6.88
0.59
−7.90%
Follow CAPR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 4 | 3 | 4 | 3 | 3 | 3 | 1 | 4 | 2 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 52.33 | 0.00 |
P/S ratio |
— | 21.82 | 5.45 | 34.30 | 223.49 | 172.12 | 4.73 | 7.21 | 13.66 | 11.83 |
Altman Z-Score |
— | 10.32 | (2.15) | (3.79) | (0.31) | 1.20 | (9.87) | (12.89) | (1.49) | (4.66) |
Altman Z″-Score (non-manufacturers) |
— | 6.08 | (8.76) | (10.05) | (3.49) | (0.52) | (19.12) | (28.50) | (7.64) | (11.03) |
P/FCF ratio |
— | 9.30 | 0.00 | 60.72 | 0.00 | 0.00 | 0.25 | 1.37 | 0.00 | 0.00 |
Beneish M-Score |
— | (2.61) | 6.51 | 0.79 | — | — | (3.62) | (3.46) | 3.38 | (3.85) |
P/Operating CF |
— | (32.85) | (11.83) | (13.70) | (12.02) | (13.90) | (2.66) | (3.20) | (13.65) | (13.60) |
P/B ratio |
— | 3.34 | 6.07 | 8.02 | 2.16 | 1.89 | 0.69 | 2.61 | 3.24 | 0.00 |
Price to Tangible BV |
— | 3.34 | 6.07 | 8.02 | 2.16 | 1.89 | 0.70 | 2.64 | 3.27 | 0.00 |
EV/Sales |
— | 15.66 | 4.44 | 24.42 | 155.13 | 112.70 | 12.33 | 19.49 | 18.60 | 10.92 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (8.72) | (4.37) | 13.69 | (2.79) | (3.48) | (1.82) | (2.35) | (3.49) | (3.02) |
EV/FCF |
— | 6.67 | (4.04) | 43.23 | (2.61) | (4.60) | 0.65 | 3.69 | (3.48) | (2.98) |
Quick Ratio |
8.88 | 7.70 | 1.59 | 1.78 | 8.53 | 10.99 | 11.11 | 6.17 | 9.10 | 3.63 |
Current Ratio |
9.01 | 7.77 | 1.63 | 1.82 | 8.82 | 11.33 | 11.74 | 6.75 | 9.40 | 3.70 |
Net Debt/EBITDA |
2.99 | 3.68 | 1.72 | 1.42 | 1.69 | 2.41 | 0.86 | 0.27 | 0.90 | 0.22 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.21% | 30.38% | 36.51% | 20.75% | 74.18% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.49 | 0.73 | 0.30 | (3.47) |
Asset Turnover |
0.00 | 0.19 | 0.46 | 0.06 | 0.01 | 0.01 | 0.10 | 0.13 | 0.15 | 0.23 |
Operating CF/Net income |
0.66 | 0.99 | 1.15 | (0.17) | 0.84 | 0.74 | 0.89 | 0.91 | (5.85) | 0.77 |
Capex/Depreciation |
131.75 | 64.73 | (1.92) | (6.30) | (4.87) | (3.81) | 17.44 | 143.84 | (0.22) | (1.54) |
Interest Coverage |
(35.51) | — | — | (56.95) | (364.15) | — | — | (112.70) | (32.25) | (49.25) |
| (46.56%) | (48.16%) | (129.63%) | (134.49%) | (67.23%) | (77.95%) | (133.42%) | (191.78%) | 67.32% | 747.04% | |
| (39.91%) | (35.31%) | (40.96%) | (63.48%) | (52.73%) | (59.73%) | (75.06%) | (119.05%) | 13.89% | (108.03%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (1,463.42%) | (2,130.18%) | 0.00% | 0.00% |
Return on Tangible Assets |
(34.39%) | (27.36%) | (88.63%) | (121.47%) | (58.72%) | (43.28%) | (75.74%) | (195.00%) | 16.87% | (137.79%) |
Average Days of Receivables |
0.00 | 169.93 | 150.36 | 78.34 | 583.94 | 0.00 | 31.96 | 44.75 | 47.17 | 20.38 |
Research and Development Expense of Revenue |
0.00% | 224.37% | 144.76% | 855.07% | 5,541.45% | 2,725.43% | 511.62% | 721.96% | 403.78% | 401.19% |
Selling, General and Administrative Expense of Revenue |
0.00% | 66.75% | 50.87% | 408.85% | 3,108.33% | 1,786.40% | 357.92% | 295.06% | 178.62% | 123.37% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
0.00% | 43.85% | 29.36% | 174.74% | 1,210.98% | 629.29% | 69.75% | 103.24% | 64.16% | 49.08% |
Graham Net Nets |
— | 0.28 | 0.11 | 0.05 | 0.39 | 0.51 | 1.32 | 0.32 | 0.29 | (0.10) |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.72 | 22.25 |
Earnings Yield |
— | (8.70%) | (16.99%) | (30.65%) | (29.69%) | (27.41%) | (168.75%) | (129.27%) | 1.91% | (40.00%) |
Free Cash Flow Yield |
— | 10.75% | (20.16%) | 1.65% | (26.62%) | (14.23%) | 401.01% | 73.15% | (39.17%) | (30.97%) |
Revenue per Share |
0.00 | 0.63 | 0.94 | 0.10 | 0.01 | 0.02 | 0.27 | 0.57 | 1.15 | 2.16 |
Operating CF per Share |
(1.50) | (1.14) | (0.96) | 0.20 | (0.73) | (0.65) | (1.84) | (4.71) | (6.14) | (7.79) |
Capex per Share |
5.35 | 2.62 | (0.08) | (0.14) | (0.05) | (0.04) | 0.81 | 7.71 | (0.01) | (0.10) |
Free Cash Flow per Share |
3.85 | 1.48 | (1.03) | 0.06 | (0.78) | (0.68) | (1.03) | 3.00 | (6.15) | (7.90) |
Cash per Share |
6.84 | 4.30 | 1.47 | 1.69 | 1.51 | 2.10 | 2.66 | 2.56 | 6.41 | 9.46 |
Shareholders Equity per Share |
6.58 | 4.13 | 0.84 | 0.48 | 1.36 | 1.81 | 1.84 | 1.57 | 4.84 | (2.16) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.58 | 4.13 | 0.84 | 0.48 | 1.36 | 1.81 | 1.84 | 1.57 | 4.84 | (2.16) |
Free Cash Flow |
179.06 | 52.26 | (27.64) | 1.56 | (18.01) | (10.60) | (3.82) | 8.82 | (14.26) | (14.65) |
Working Capital |
287.10 | 142.36 | 19.59 | 19.30 | 32.30 | 30.71 | 9.65 | 7.22 | 14.04 | 13.21 |
Capital Expenditures |
248.87 | 92.26 | (2.05) | (3.36) | (1.20) | (0.55) | 3.00 | 22.68 | (0.03) | (0.19) |
Net Current Asset Value |
272.78 | 138.37 | 14.72 | 4.58 | 26.47 | 27.26 | 6.27 | 3.84 | 10.67 | (4.64) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | (4.14) | 0.08 | 1.32 | 4.88 | 1.76 | (2.99) | (13.57) | 0.01 | 0.05 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.10 | 0.26 | 0.19 | 0.12 | 0.14 | 0.17 | 0.39 | 0.27 | 0.39 | 0.29 |
Cash ROIC |
28.70% | 17.60% | (44.52%) | 2.93% | (27.18%) | (17.40%) | (19.01%) | 56.79% | (48.40%) | (53.37%) |
Accounts Receivable Turnover |
0.00 | 2.15 | 4.61 | 5.43 | 1.02 | 0.00 | 6.86 | 6.08 | 9.39 | 18.38 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Receivables |
5.21 | 10.37 | 5.46 | 0.47 | 0.24 | — | 0.15 | 0.27 | 0.28 | 0.22 |
Average Payables |
2.47 | 4.77 | 5.59 | 4.32 | 3.22 | 1.81 | 1.08 | 1.46 | 2.60 | 3.21 |
Average Assets |
263.22 | 114.61 | 54.41 | 45.71 | 37.97 | 22.87 | 10.18 | 12.76 | 17.51 | 17.41 |
Average Common Equity |
225.63 | 84.03 | 17.19 | 21.58 | 29.78 | 17.52 | 5.73 | 7.92 | 3.61 | (2.52) |
Columns are period end dates